ESR1 and breast carcinoma: Upregulated expression of ERα serves as a survival mechanism upon permanent HER2 inhibition, while increased signaling through HER2 and/or other members of the HER-family has been shown to mediate resistance to endocrine therapies in ERα+ breast cancer cells [18, 19].